Xenetic Biosciences is trading 6.19% down at $3.18, despite the broader biotechnology sector rising 2.02% during regular trading.
- No fresh company-specific announcement or clearly identified catalyst was found for August 21, 2026.
- Results released August 7 showed a second-quarter loss of $930,000, or $0.41 per share, on $661,000 in revenue, but appear stale rather than a direct explanation for today’s decline.